Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

An organ system based approach to prognosis in advanced melanoma.

Holtan SG, Mansfield AS, Creedon DJ, Nevala WK, Haluska P, Leontovich AA, Markovic SN.

Front Biosci (Elite Ed). 2012 Jun 1;4:2723-33.

PMID:
22652681
3.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D.

J Transl Med. 2011 Nov 28;9:204. doi: 10.1186/1479-5876-9-204.

4.

Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.

Fortes C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Zappalà A, Annessi G, Marino C, Caggiati A, Russo N, Michelozzi P.

Melanoma Res. 2015 Aug;25(4):306-11. doi: 10.1097/CMR.0000000000000164.

PMID:
25933208
5.

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS.

J Clin Oncol. 2007 Mar 1;25(7):869-75.

PMID:
17327608
6.

Breast cancer stem cells phenotype and plasma cell-predominant breast cancer independently indicate poor survival.

Wei H, Fu P, Yao M, Chen Y, Du L.

Pathol Res Pract. 2016 Apr;212(4):294-301. doi: 10.1016/j.prp.2016.01.008. Epub 2016 Jan 27.

PMID:
26857534
7.

Association of galectin-3 expression with melanoma progression and prognosis.

Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW.

Eur J Cancer. 2012 Apr;48(6):865-74. doi: 10.1016/j.ejca.2011.09.003. Epub 2011 Nov 7.

PMID:
22071132
8.

Cell cycle gene networks are associated with melanoma prognosis.

Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, Ranjard L, Derkac E, Imoto S, Miyano S, Crampin EJ, Print CG.

PLoS One. 2012;7(4):e34247. doi: 10.1371/journal.pone.0034247. Epub 2012 Apr 20.

9.

Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment.

Camisaschi C, Vallacchi V, Castelli C, Rivoltini L, Rodolfo M.

Expert Rev Mol Diagn. 2014 Jul;14(6):643-6. doi: 10.1586/14737159.2014.928206. Epub 2014 Jun 10.

PMID:
24914691
10.

Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.

Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I, Cosci E, Tosi P, Luzi P.

Oncol Rep. 2007 Nov;18(5):1115-22.

PMID:
17914561
11.

99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.

Signore A, Annovazzi A, Barone R, Bonanno E, D'Alessandria C, Chianelli M, Mather SJ, Bottoni U, Panetta C, Innocenzi D, Scopinaro F, Calvieri S.

J Nucl Med. 2004 Oct;45(10):1647-52.

12.

Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.

Schatton T, Scolyer RA, Thompson JF, Mihm MC Jr.

Methods Mol Biol. 2014;1102:287-324. doi: 10.1007/978-1-62703-727-3_16. Review.

PMID:
24258985
14.

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.

de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjatic S, Remark R, Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA, Birge MB, Phelps RG, Saenger YM.

Cancer Immunol Immunother. 2015 Sep;64(9):1193-203. doi: 10.1007/s00262-015-1726-0. Epub 2015 Jun 16.

15.

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.

Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M.

Oncotarget. 2015 Dec 1;6(38):40836-49. doi: 10.18632/oncotarget.5696.

16.

Prognostic impact of B-cell density in cutaneous melanoma.

Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J, Tímár J.

Cancer Immunol Immunother. 2011 Dec;60(12):1729-38. doi: 10.1007/s00262-011-1071-x. Epub 2011 Jul 21.

PMID:
21779876
17.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K.

Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429.

18.

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A.

J Natl Cancer Inst. 2015 Dec 30;108(6):djv406. doi: 10.1093/jnci/djv406. Print 2016 Jun.

19.

Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.

Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn JH, Gong G.

Am J Clin Pathol. 2015 Aug;144(2):278-88. doi: 10.1309/AJCPIXUYDVZ0RZ3G.

PMID:
26185313
20.

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.

Supplemental Content

Support Center